Piper Jaffray analyst Charles Duncan reiterates Overweight rating and $40 price target on Aimmune Therapeutics (NASDAQ: AIMT), as the company ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE